Trial
NCT02605356
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Multiple Myeloma
Intervention
Radium-223 dichloride (Xofigo, BAY88-8223)
Why stopped
Study restarted under new study number 18987
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-07